How Is Lung Cancer Treatment Planned for Each Patient?

How Is Lung Cancer Treatment Planned for Each Patient?

How Is Lung Cancer Treatment Planned for Each Patient? The answer depends on several important details, including the type of lung cancer, its stage, the patient’s general health and the results of specialised tests. Two people may have lung cancer, but they may not need the same treatment. One person may benefit from surgery, while another may need chemotherapy, radiation therapy, targeted therapy or immunotherapy. Doctors carefully study each patient’s condition before recommending a treatment plan.

Lung cancer treatment is not selected using a single test or a standard plan for everyone. The medical team considers how the cancer is growing, whether it has spread, which changes are present in the cancer cells and how well the patient can manage treatment. The patient’s preferences, daily activities and other health conditions are also important. A medical oncologist helps explain the available choices, expected benefits and possible side effects so that patients and their families can make informed decisions.

1. Confirming the Lung Cancer Diagnosis

The first step in treatment planning is to confirm whether a person has lung cancer. Doctors review the patient’s symptoms, medical history and examination findings. Symptoms such as a persistent cough, coughing up blood, chest discomfort, unexplained weight loss or breathlessness may lead to further investigations. However, these symptoms can also occur because of other health conditions. A doctor therefore needs appropriate tests before deciding whether cancer is present.

A biopsy is often important because it allows a small sample of tissue or cells to be examined in a laboratory. The report can help identify the type of lung cancer. Imaging tests, such as CT scans and PET scans, may provide additional information about the tumour and its location. In some cases, bronchoscopy or another procedure is needed to collect a sample. Accurate diagnosis gives the oncology team the information needed to discuss suitable treatment approaches.

 

NCI+2

2. Identifying the Type of Lung Cancer

Lung cancer is mainly divided into two broad types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Non-small cell lung cancer is more common and includes subtypes such as adenocarcinoma and squamous cell carcinoma. Small cell lung cancer is less common but can grow and spread more quickly. The type is identified by examining cancer cells or tissue under a microscope.

Identifying the cancer type is important because different cancers may respond to different treatments. For example, surgery may be considered for selected patients with early-stage non-small cell lung cancer. Small cell lung cancer is commonly treated with medicines such as chemotherapy, sometimes combined with immunotherapy and radiation therapy. The doctor also considers whether further tests are needed to understand the cancer’s characteristics. This information helps prevent a treatment plan from being chosen based only on the name of the disease.

 

NCI+2

3. Finding the Stage and Spread of Lung Cancer

Cancer staging describes the size of the tumour and whether it has spread to nearby lymph nodes or distant organs. Doctors use imaging tests, biopsy findings and other investigations to determine the stage. A cancer that is limited to a small area of the lung may be considered early-stage disease. If it has reached nearby lymph nodes or structures, it may be locally advanced. Cancer that has spread to distant parts of the body is described as metastatic or advanced disease.

Staging is one of the major factors used to decide how treatment should be planned. Some early-stage cancers may be treated with surgery or focused radiation therapy. Locally advanced disease may need a combination of chemotherapy and radiation therapy, with other medicines considered in suitable cases. Advanced lung cancer may be managed with systemic treatments such as chemotherapy, targeted therapy or immunotherapy. The exact plan depends on the cancer type and other test results, not the stage alone.

 

NCI+2

4. Checking Molecular and Biomarker Test Results

Some lung cancer cells contain specific genetic changes or proteins that influence how the cancer grows. These are often called biomarkers. Molecular testing can identify certain changes, including EGFR, ALK and ROS1 alterations in appropriate cases. Other tests may assess proteins such as PD-L1. The doctor may recommend these tests using a sample collected during a biopsy. In some situations, a blood-based test may also provide useful information.

The results can help the oncologist decide whether a patient may benefit from targeted therapy or immunotherapy. For example, if a tumour has a particular genetic alteration, a medicine designed to act on that alteration may be considered. If the test does not show a suitable target, a different treatment approach may be recommended. Not every patient has the same biomarkers, and not every medicine is suitable for every result. Testing helps make treatment decisions more specific to the cancer rather than relying on a general approach.

 

NCI+2

5. Assessing the Patient’s Overall Health

The treatment plan must consider the whole person, not just the tumour. Doctors review the patient’s age, heart and lung function, kidney and liver health, nutritional condition and other medical problems. They may also ask about daily activities, such as walking, eating, bathing and completing household tasks. These details help the team understand how well the patient may tolerate a particular treatment.

For example, a patient with good lung function may be able to undergo an operation, while someone with serious breathing problems may need another approach. A person with certain kidney or heart conditions may require changes to medicines or closer monitoring. Doctors may request blood tests, lung function tests or a specialist assessment before treatment begins. This careful review helps balance the expected benefits of cancer treatment with possible risks and the patient’s ability to recover.

 

Cancer Institute NSW+2

6. Selecting the Most Suitable Treatment Method

After reviewing the diagnosis, cancer type, stage, biomarkers and general health, the oncology team discusses possible treatment methods. These may include surgery, chemotherapy, radiation therapy, targeted therapy and immunotherapy. Surgery aims to remove the tumour and may be suitable for selected early-stage cancers. Chemotherapy uses medicines to destroy or slow the growth of cancer cells. Radiation therapy uses carefully directed energy to damage cancer cells in a particular area.

Targeted therapy acts on specific changes that help cancer cells grow, while immunotherapy helps the immune system recognise and attack cancer cells. Some patients may receive one treatment, while others may need a combination. For instance, chemotherapy may be given with radiation therapy, or medicines may be used before or after surgery in selected cases. The doctor explains why a particular method is being considered and what the treatment is expected to achieve.

 

NCI+2

7. Planning the Order and Duration of Treatment

Treatment planning also involves deciding when each treatment should begin and how different methods should be arranged. Some patients receive treatment before surgery to help reduce the tumour or treat cancer cells beyond the main tumour. This is known as neoadjuvant treatment. Other patients may receive additional treatment after surgery to reduce the risk of the cancer returning. This is called adjuvant treatment.

The number of treatment sessions and the time between them depend on the medicines, radiation schedule, surgery and the patient’s response. Chemotherapy is often given in cycles, with recovery periods between sessions. Radiation therapy may involve a planned series of appointments. Targeted therapy and immunotherapy may follow different schedules. The oncology team explains the expected timeline, follow-up tests and possible delays. If side effects or changes in health occur, the schedule may need to be reviewed.

 

NCI+1

8. Considering the Patient’s Preferences and Daily Needs

A good treatment plan should be discussed with the patient and, when the patient wishes, their family. People may have questions about treatment benefits, side effects, travel, time away from work, cost and the effect on daily routines. Some patients may also want to discuss fertility preservation before treatment, especially if having children in the future is important to them. These concerns should be shared with the doctor before treatment starts.

When families ask How Is Lung Cancer Treatment Planned for Each Patient?, the patient’s own needs are an important part of the answer. The doctor should explain the purpose of treatment in clear language and allow time for questions. Patients can ask what may happen if they choose one option over another, how side effects will be managed and when progress will be checked. A second medical opinion may also be considered if the patient wants further clarification. Shared decision-making helps patients take an active role in their care.

 

Cancer Institute NSW+1

9. Working With a Multidisciplinary Cancer Care Team

Lung cancer care may involve several medical specialists because each professional contributes a different area of knowledge. A medical oncologist focuses on cancer medicines such as chemotherapy, immunotherapy and targeted therapy. A thoracic surgeon assesses whether an operation may be suitable. A radiation oncologist plans radiation treatment. Pulmonologists, radiologists, pathologists, nurses and supportive-care professionals may also contribute to diagnosis and care.

The specialists may discuss the patient’s reports and treatment choices together through a multidisciplinary team approach. This helps ensure that important details, such as tumour location, biopsy findings, stage and general health, are considered before a plan is finalised. The team may also review the plan if new test results become available or the patient’s condition changes. Dr. Bibin Francis’s official profile describes his work in medical oncology, including lung cancer care, chemotherapy, immunotherapy, targeted therapy and a multidisciplinary approach in Thrissur.

 

Thrissur+2

10. Monitoring Treatment Response and Adjusting the Plan in Thrissur

Treatment planning does not end when the first medicine or procedure is given. Doctors arrange follow-up appointments to check how the patient is responding. These reviews may include discussions about symptoms, physical examinations, blood tests and imaging scans. The timing and type of tests depend on the treatment being used and the patient’s condition. The results help the medical team understand whether the cancer is shrinking, remaining stable or growing.

If the treatment is working and side effects are manageable, the doctor may continue the planned approach. If the cancer changes or side effects become difficult, the team may consider adjusting the dose, changing medicines or discussing another treatment option. Patients should report new symptoms rather than waiting until the next appointment. People seeking lung cancer treatment in Thrissur can consult a qualified medical oncologist to discuss their reports and individual care needs. Dr. Bibin Francis is a Medical Oncologist and Assistant Professor in the Department of Medical Oncology at Jubilee Mission Medical College & Research Institute, Thrissur.

Table of Content

Dr. Bibin Francis
Cancer Care Specialist

Dr. Bibin Francis

Medical Oncologist & Assistant Professor

Dr. Bibin Francis is a dedicated medical oncologist with expertise in chemotherapy, immunotherapy, targeted therapy, and personalized cancer treatment planning for a wide range of malignancies.

Jubilee Mission Medical College & Research Institute, Thrissur, Kerala

Frequently Asked Questions

Lung cancer treatment is planned by considering the cancer type, stage, tumour characteristics, molecular test results and the patient's overall health. Doctors may review imaging reports, biopsy findings and other investigations before recommending a treatment approach. The plan may include surgery, chemotherapy, immunotherapy, targeted therapy, radiation therapy or a combination of treatments, depending on individual needs.

Several factors influence treatment planning, including the type and stage of lung cancer, tumour location, molecular characteristics, age, general health and existing medical conditions. Doctors also consider the patient's preferences, treatment goals and ability to tolerate particular therapies. These factors help determine which options may be appropriate.

Yes. The stage of lung cancer is an important factor in choosing treatment. Early-stage disease may be managed with surgery or other local treatments in suitable patients. Locally advanced or metastatic lung cancer may require systemic treatments such as chemotherapy, immunotherapy or targeted therapy. The recommended approach depends on the complete clinical assessment.

A biopsy provides tissue or cell samples that can be examined to confirm whether cancer is present and identify its type. This information helps doctors distinguish between different forms of lung cancer. Biopsy findings, along with imaging and other investigations, guide decisions about suitable treatment options.

Molecular testing looks for specific genetic changes and biomarkers in tumour samples. These findings can help identify patients who may benefit from targeted therapy or certain immunotherapy approaches. The need for testing depends on the lung cancer type and clinical situation. Doctors use the results alongside other medical information when selecting treatment.

No. Chemotherapy and immunotherapy are not required for every patient. Their suitability depends on the cancer type, stage, molecular findings, overall health and treatment goals. Some patients may receive surgery, radiation therapy or targeted therapy instead, while others may benefit from a combination of treatments. The medical oncologist explains the available options.

A patient's general health, lung function, kidney and liver function, existing medical conditions and daily activity level can influence treatment decisions. Doctors may recommend additional assessments before starting therapy. These evaluations help determine whether a particular treatment is suitable and whether adjustments or supportive care are needed.

Yes. Treatment plans may be adjusted according to how the cancer responds, changes in the patient's health, treatment side effects and new investigation results. Doctors may recommend continuing, modifying or changing treatment when clinically appropriate. Regular reviews help the medical team assess progress and make informed decisions.

A multidisciplinary team may include medical oncologists, surgical specialists, radiation oncologists, radiologists, pathologists and other healthcare professionals. Each specialist contributes expertise to the evaluation and treatment process. Collaborative discussion helps the team consider different treatment approaches and coordinate care according to the patient's clinical needs.

A medical oncologist reviews the diagnosis, cancer stage, biopsy findings and relevant test results to discuss suitable systemic treatment options. The specialist explains potential benefits, side effects and follow-up requirements. Dr. Bibin Francis, Medical Oncologist in Thrissur, provides specialist guidance in lung cancer care, helping patients understand their diagnosis and discuss an appropriate treatment plan.

Scroll to Top